Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Logistic regression showed that the probability of reducing fractures for each anti-osteoporotic treatment considered was independent of sex, age, and the number of comorbidities, increasing significantly only in males taking vitamin D (OR = 7.918), patients without comorbidities taking vitamin D (OR = 4.197) and patients with ≥ 3 comorbidities taking calcium (OR = 9.412).

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

For this retrospective observational study, data from baseline and follow-up visits on the number of comorbidities, prescribed anti-osteoporotic treatment and vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression and an artificial network model.

Source: Abstract.

We analyzed the number of comorbidities, the anti-osteoporotic treatment prescribed and the occurrence of vertebral, humerus or hip fractures at two visits, a baseline visit when patients were first referred to the internal medicine consultation for the evaluation or diagnosis of osteoporosis or fractures, and a follow-up visit at ≥ 1 year.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry

Observational study · Aging Clinical and Experimental Research · 2022

Original publication title

Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry

María Begoña Coco Martín; Luis Leal Vega; José Antonio Blázquez Cabrera; Amalia Navarro; María Jesús Moro; Francisca Arranz García; María José Amérigo; Manuel Sosa Henríquez; María Ángeles Vázquez; María José Montoya; Manuel Díaz Curiel; José Manuel Olmos; José Luis Pérez Castrillón; OSTEOMED GroupFilgueira RubioJoséSánchez MoliniPilarAguado CaballeroJosé MaríaArmengol SucarratsDolorsCalero BernalMaría Luzde Escalante YanguasBegoñaHernández de SosaNereaHernándezJosé LuisJareño ChaumelJuliaMiranda GarcíaMaría JoséGiner GarcíaMercedesMiranda DíazCristinaCotos CancaRafaelCobeta GarcíaJuan CarlosRodero HernándezFrancisco JavierTirado MirandaRaimundo

© The Author(s) 2022

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

To examine the response to anti-osteoporotic treatment, considered as incident fragility fractures after a minimum follow-up of 1 year, according to sex, age, and number of comorbidities of the patients.

Source: Purpose

Abstract: What methods does the paper describe?

For this retrospective observational study, data from baseline and follow-up visits on the number of comorbidities, prescribed anti-osteoporotic treatment and vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression and an artificial network model.

Source: Methods

Abstract: Results

Logistic regression showed that the probability of reducing fractures for each anti-osteoporotic treatment considered was independent of sex, age, and the number of comorbidities, increasing significantly only in males taking vitamin D (OR = 7.918), patients without comorbidities taking vitamin D (OR = 4.197) and patients with ≥ 3 comorbidities taking calcium (OR = 9.412). Logistic regression correctly classified 96% of patients (Hosmer: Lemeshow = 0.492) compared with the artificial neural network model, which correctly classified 95% of patients (AUC = 0.6).

Source: Results

Abstract: Conclusion

In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.

Source: Conclusion
Authors’ abstract

Purpose

To examine the response to anti-osteoporotic treatment, considered as incident fragility fractures after a minimum follow-up of 1 year, according to sex, age, and number of comorbidities of the patients.

Methods

For this retrospective observational study, data from baseline and follow-up visits on the number of comorbidities, prescribed anti-osteoporotic treatment and vertebral, humerus or hip fractures in 993 patients from the OSTEOMED registry were analyzed using logistic regression and an artificial network model.

Results

Logistic regression showed that the probability of reducing fractures for each anti-osteoporotic treatment considered was independent of sex, age, and the number of comorbidities, increasing significantly only in males taking vitamin D (OR = 7.918), patients without comorbidities taking vitamin D (OR = 4.197) and patients with ≥ 3 comorbidities taking calcium (OR = 9.412). Logistic regression correctly classified 96% of patients (Hosmer: Lemeshow = 0.492) compared with the artificial neural network model, which correctly classified 95% of patients (AUC = 0.6).

Conclusion

In general, sex, age and the number of comorbidities did not influence the likelihood that a given anti-osteoporotic treatment improved the risk of incident fragility fractures after 1 year, but this appeared to increase when patients had been treated with risedronate, strontium or teriparatide. The two models used classified patients similarly, but predicted differently in terms of the probability of improvement, with logistic regression being the better fit.

Publication and source details

Original title: Comorbidity and osteoporotic fracture: approach through predictive modeling techniques using the OSTEOMED registry

María Begoña Coco Martín; Luis Leal Vega; José Antonio Blázquez Cabrera; Amalia Navarro; María Jesús Moro; Francisca Arranz García; María José Amérigo; Manuel Sosa Henríquez; María Ángeles Vázquez; María José Montoya; Manuel Díaz Curiel; José Manuel Olmos; José Luis Pérez Castrillón; OSTEOMED GroupFilgueira RubioJoséSánchez MoliniPilarAguado CaballeroJosé MaríaArmengol SucarratsDolorsCalero BernalMaría Luzde Escalante YanguasBegoñaHernández de SosaNereaHernándezJosé LuisJareño ChaumelJuliaMiranda GarcíaMaría JoséGiner GarcíaMercedesMiranda DíazCristinaCotos CancaRafaelCobeta GarcíaJuan CarlosRodero HernándezFrancisco JavierTirado MirandaRaimundo

Aging Clinical and Experimental Research · 2022

© The Author(s) 2022https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Universidad de Valladolid

Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T09:33:13.477446+00:00

DOI: 10.1007/s40520-022-02129-5 · PMC9464169